Investing in early-stage biotechs is always risky and almost never easy, and that has certainly been true for Aptose Biosciences (NASDAQ:APTO). Investors have had to deal with unexpected issues tied to its former lead drug luxeptinib and a slow build of positive clinical data for its new lead drug tuspetinib (formerly HM43239, or "239"), and all this while the biotech market has been under pressure.
Heading toward the American Society of Hematology (or ASH) meeting in mid-December, Aptose has been building up its clinical dataset for tuspetinib, and so far this looks like a promising drug worth more than the sub-$70M market capitalization of Aptose as of this writing. Of course, there is still a lot that has to be proven in the clinic, but investors looking for a high-risk play on difficult-to-treat leukemia subtypes should take a closer look.
Follow the link to the full article:
Aptose Biosciences: Expansion Studies Could Rebuild Investor Interest In This Beaten-Down Biotech
No comments:
Post a Comment